EcoDrugPlus

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSSFOG00015014257
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSSFOG00015023738
Gene Symbol: LOC108931316
3 Cross references
210 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSSFOG00015009780
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSSFOG00015007024
Gene Symbol: BTK
1 Cross references
137 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSSFOG00015018658
Gene Symbol: LOC108937495
3 Cross references
188 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSSFOG00015020182
Gene Symbol: CCR9
3 Cross references
193 Possible Orthologues:

C-X-C Chemokine Receptor Type 4-Like

Ensembl ID : ENSSFOG00015012893
Gene Symbol: LOC108928927
3 Cross references
133 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSSFOG00015009259
Gene Symbol: CXCR1
1 Cross references
275 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSSFOG00015023648
Gene Symbol: CXCR4
3 Cross references
209 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSSFOG00015013079
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

D(1) Dopamine Receptor-Like

Ensembl ID : ENSSFOG00015000350
Gene Symbol: LOC108934257
3 Cross references
198 Possible Orthologues:

D(2) Dopamine Receptor A-Like

Ensembl ID : ENSSFOG00015009581
Gene Symbol: LOC108936095
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).